CoChat

Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 1 of the 34 sources its claims cite were checked for support.

Abstract

PURPOSE: Immune checkpoint inhibitors (ICIs) are frequently used to treat metastatic solid tumors characterized by high tumor mutational burden (TMB) and/or mismatch repair (MMR) deficiency. Most of the literature on their benefit is about carcinomas and melanomas, but little is known about their effects on sarcomas in these settings. In this study, we examined the response pattern to ICI-based therapy in sarcomas with those characteristics. Methods: Patients treated in our institution with ICI-based therapy for sarcomas with high TMB and/or MMR deficiency were identified. We analyzed the main outcome of interest, radiologic response to therapy, alongside clinical information including treatment type and duration, histologic diagnosis, germline and somatic MMR deficiency, and ultraviolet A (UVA) mutational signature. RESULTS: Among 17 patients identified, TMB ranged from 9 to 151 mut/Mb. Radiologic response was observed in 6 patients. TMB of responding patients ranged from 15-75 mut/Mb. The only responding case of MMR deficiency was seen in the one patient diagnosed with Lynch syndrome. By contrast, none of the five cases of sporadic MMR deficiency responded. The three complete responses were seen in MMR-proficient tumors associated with UVA signature and high TMB. CONCLUSION: Overall, sarcomas with MMR deficiency and/or high TMB show a heterogeneous pattern of responses to ICI-based therapy. Other cellular and molecular factors, such as histology, germline factors, and mutation signatures, likely contribute to the response to ICI treatment in sarcomas.

Overview

CoChat Summary

## TL;DR

This retrospective single-center case series examined immune checkpoint inhibitor (ICI) responses in 17 patients with metastatic sarcomas selected for high tumor mutational burden (TMB) and/or mismatch repair deficiency (MMR-D). Objective responses occurred in 6 of 17 patients, but responses clustered in tumors with ultraviolet A (UVA) mutation signatures and in one germline Lynch syndrome case, suggesting TMB/MMR-D alone were not sufficient predictors.

## Key findings

  • Among 17 patients, 6 had objective responses to ICI therapy: 3 complete responses and 3 partial responses; 2 had stable disease and 9 had primary progression.
  • Of the 16 high-TMB cases (TMB 10 to 151 mutations/Mb; one case had TMB 9), 6 responded, which the authors report as 37%.
  • Of the 6 MMR-D cases, 1 responded; this response was in the single patient with germline MMR deficiency / Lynch syndrome, while none of the somatic MMR-D cases showed radiologic response.
  • The 3 complete responses occurred in MMR-proficient tumors with UVA signatures: 2 pleomorphic dermal sarcomas and 1 cutaneous angiosarcoma; the authors note that all four cases with a UVA signature responded.

## Methods

  • Design: Retrospective chart review at a single cancer center, approved by the Institutional Review Board.
  • Sample/data: 17 patients aged 30–73 years, all with metastatic sarcoma; inclusion required TMB ≥10 mutations/Mb or MMR-D by next-generation sequencing, with biomarkers mostly confirmed on tumor samples and in one case by liquid biopsy.
  • Analysis: Investigators assessed response using published real-world response criteria based on imaging (mostly CT every ~6 weeks; PET-CT for angiosarcoma of bone) and summarized responses by TMB, MMR status, histology, and mutation signature.

## Limitations

  • The paper states that the sample size was small and therefore does not allow definitive statements about differences between germline and somatic MMR deficiency.
  • The authors note that their real-world response criteria are less standardized than RECIST and may be more prone to bias or variable reliability; this is a limitation explicitly stated in the text.
  • Evident from the text: this was a retrospective, single-center series with heterogeneous sarcoma subtypes and prior treatments, and the authors performed no statistical analysis of the TMB-response relationship.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1200/po-26-00414

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

1 Valid · 0 Not valid · 20 Not checked · 22 Own results and interpretations

8 more claims

Create a free account to see all 43 claims and to verify the 33 references still open.

See all claims — free account
  • It may state two separate claims as one. 16
  • Probably not a substantial claim. 18
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. McKelvey BA, Garrett-Mayer E, Rivera DR, et al: Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in patients with metastatic non-small cell lung cancer treated with chemotherapy. JCO Clin Cancer Inform 10.1200/CCI.24.00091 · doi:10.1200/cci.24.00091

Cited by

Still being checked.

Metadata

Authors
Alcindor, T., Papke, D. J., Venkataraman, V., Wagner, M. J., Merriam, P., Haddox, C. L., Wagner, A. J., Solimini, N. L., Jambhekar, A., & George, S.
Affiliations
  • Harvard University (US)
  • Brigham and Women's Hospital (US)
  • Dana-Farber Cancer Institute (US)
Corresponding author
Alcindor, Thierry
Venue
JCO Precision Oncology
Published
2026-07
Volume
10
Issue
7
Pages
e2600414-e2600414
ISSN
2473-4284 (ISSN-L)
OpenAlex
W7167469011
Cited by
0
References
32
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • JCO Precision Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • GlaxoSmithKline
  • Eisai
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
immune checkpoint inhibitors, sarcoma, tumor mutational burden, mismatch repair deficiency, Lynch syndrome, radiological response, treatment response heterogeneity
MeSH terms
Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Brain Neoplasms, Female, Humans, Male, Middle Aged, Neoplastic Syndromes, Hereditary, Sarcoma, Colorectal Neoplasms, Tumor Burden, DNA Mismatch Repair

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency. https://app.cochat.ai/papers/10.1200/po-26-00414
The paper
Alcindor, T., Papke, D. J., Venkataraman, V., Wagner, M. J., Merriam, P., Haddox, C. L., Wagner, A. J., Solimini, N. L., Jambhekar, A., & George, S. (2026). Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency. JCO Precision Oncology. https://doi.org/10.1200/po-26-00414

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.